Last updated: September 29, 2026
Accuretic, Pfizer’s fixed-dose combination of quinapril hydrochloride and hydrochlorothiazide, has no meaningful remaining exclusivity or premium-brand economics. FDA approval dates to the late 1980s, generic competition eroded pricing for years, and Pfizer discontinued distribution after detecting elevated levels of the nitrosamine impurity N-nitroso-quinapril. The product’s commercial trajectory is now defined by withdrawal, therapeutic substitution, and generic availability rather than brand growth.
What is Accuretic and what market did it serve?
Accuretic combines an angiotensin-converting enzyme inhibitor, quinapril, with the thiazide diuretic hydrochlorothiazide.
| Attribute |
Accuretic |
| Active ingredients |
Quinapril hydrochloride and hydrochlorothiazide |
| Drug class |
ACE inhibitor/thiazide combination |
| Indication |
Hypertension |
| Original sponsor |
Pfizer |
| Dosage forms |
Oral tablets |
| Market position |
Branded legacy antihypertensive |
| Key strengths |
10 mg/12.5 mg, 20 mg/12.5 mg, and 20 mg/25 mg |
| FDA status |
Discontinued commercial product |
| Primary commercial issue |
Nitrosamine-related withdrawal and generic substitution |
| Biosimilar exposure |
Not applicable; Accuretic is a small-molecule drug |
Accuretic was prescribed when blood-pressure control required both renin-angiotensin-system inhibition and diuretic therapy in a single tablet. Its clinical alternatives include separate quinapril and hydrochlorothiazide tablets, other ACE inhibitor/thiazide combinations, angiotensin-receptor blocker/thiazide combinations, calcium-channel-blocker combinations, and low-cost generic monotherapies.
What is the FDA regulatory status of Accuretic?
Accuretic is no longer commercially supplied by Pfizer. FDA records place the product in the discontinued-product framework rather than treating the original approval as revoked for lack of efficacy.
Pfizer recalled all lots of Accuretic in 2022 after testing identified levels of N-nitroso-quinapril above acceptable daily intake limits. Nitrosamines are process-related impurities that have affected multiple products across the pharmaceutical industry. FDA advised patients not to stop antihypertensive therapy without consulting a healthcare professional because uncontrolled hypertension creates immediate clinical risk. Patients were directed toward alternative treatment rather than abrupt discontinuation.
Accuretic FDA timeline
| Date |
Event |
| Late 1980s |
FDA approval of quinapril/hydrochlorothiazide tablets |
| 1990s-2000s |
Generic competition reduces brand pricing and share |
| 2010s |
Accuretic remains a legacy antihypertensive with limited commercial differentiation |
| 2022 |
Pfizer recalls Accuretic lots because of elevated N-nitroso-quinapril |
| 2022 onward |
Brand distribution ends; prescribers transition patients to alternatives |
| Current commercial position |
No active branded growth platform and no meaningful exclusivity value |
The FDA’s 2022 communication focused on the impurity and product recall. It did not identify a new clinical efficacy concern with quinapril or hydrochlorothiazide as therapeutic classes.[1]
When did Accuretic lose exclusivity?
Accuretic’s core composition-of-matter and product exclusivity expired decades ago. The product entered a mature generic market long before its 2022 withdrawal.
The relevant commercial conclusion is straightforward:
- No current composition-of-matter exclusivity protects quinapril.
- No current branded market exclusivity protects the quinapril/hydrochlorothiazide combination.
- Any historical formulation or combination patents would have expired before the 2022 recall.
- The product is not a biologic and has no biosimilar exclusivity period.
- FDA approval history, rather than active patent protection, is the relevant regulatory record.
What patents protect Accuretic?
No active patent estate is expected to constrain generic substitution for Accuretic. The original combination was approved sufficiently long ago that ordinary United States patent terms would have ended before the current period.
A precise current patent valuation therefore produces a zero or near-zero result for practical exclusivity. The main remaining IP issues concern manufacturing know-how, impurity controls, analytical methods, and process economics. Those rights do not recreate market exclusivity for the approved product.
What is the Orange Book status of Accuretic?
Accuretic’s commercial relevance in the Orange Book is limited because the product has been discontinued and its historical exclusivity has expired. The Orange Book distinguishes discontinued products from products withdrawn for safety or effectiveness reasons. A discontinued listing does not create a continuing branded market position.
Orange Book implications
| Issue |
Accuretic assessment |
| Active brand sales |
No |
| Active patent-based barrier |
None of practical significance |
| Paragraph IV exposure |
Historical generic litigation may have existed, but no current launch barrier is material |
| Exclusivity remaining |
None |
| Product withdrawal |
Commercial discontinuation following impurity-related recall |
| Generic substitution |
High, where approved products remain available |
| Regulatory pathway for alternatives |
Abbreviated New Drug Application, or ANDA, for generics |
A generic manufacturer seeking approval for quinapril/hydrochlorothiazide would generally rely on the reference product’s established safety and efficacy through the ANDA pathway, subject to current manufacturing, bioequivalence, and impurity-control requirements.[2]
What caused Accuretic’s market withdrawal?
The withdrawal was driven by N-nitroso-quinapril contamination, not by loss of antihypertensive efficacy.
The impurity risk created several commercial consequences:
- Pfizer had to stop distribution and recall affected lots.
- Pharmacies and wholesalers removed available inventory.
- Physicians shifted patients to other ACE inhibitor combinations or separate tablets.
- Any remaining brand pricing power disappeared.
- Manufacturers faced higher analytical and process-control requirements.
- Generic manufacturers had to assess whether their own quinapril products had similar impurity risks.
The recall also reduced the strategic value of quinapril as a commercial franchise. Even if supply could be restored, the product would face an old molecule, extensive generic competition, limited differentiation, and increased quality-control costs.
How did Accuretic’s financial trajectory develop?
Accuretic followed the standard lifecycle of an older branded combination medicine.
Commercial lifecycle
| Phase |
Financial characteristics |
| Launch and early adoption |
Brand pricing supported by physician familiarity and combination convenience |
| Patent-protected period |
Higher gross margin and limited direct substitution |
| Generic entry |
Rapid price compression and loss of branded prescription volume |
| Mature generic period |
Low-value residual sales, often concentrated in formularies and legacy patients |
| 2022 recall |
Revenue interruption and inventory write-offs |
| Post-withdrawal |
No credible standalone revenue-growth path |
Pfizer does not generally report Accuretic as a separately disclosed revenue line in public financial statements. Revenue is typically aggregated into broader product or business segments. As a result, no reliable public product-level sales series establishes annual Accuretic revenue, EBITDA, or contribution margin.
The economic profile can still be assessed:
- Revenue exposure was likely immaterial to Pfizer’s consolidated results by the time of withdrawal.
- The product had limited pricing power because generic alternatives were available.
- The combination’s main residual value was prescription inertia and tablet convenience.
- The 2022 recall converted a low-growth legacy product into a discontinued asset.
- Future revenue from the branded product is effectively zero unless Pfizer reverses its commercial decision and resolves the impurity issue.
What is the generic and competitive landscape for Accuretic?
Accuretic competes in a crowded hypertension market. The relevant alternatives are not limited to identical quinapril/hydrochlorothiazide products.
Direct and indirect competitors
| Competitive category |
Examples |
| Same active ingredients |
Generic quinapril/hydrochlorothiazide tablets, where marketed |
| Separate-component therapy |
Generic quinapril plus generic hydrochlorothiazide |
| Other ACE inhibitor/thiazide combinations |
Lisinopril/hydrochlorothiazide, enalapril/hydrochlorothiazide, benazepril/hydrochlorothiazide |
| ARB/thiazide combinations |
Losartan/hydrochlorothiazide, valsartan/hydrochlorothiazide, irbesartan/hydrochlorothiazide |
| Non-combination therapy |
ACE inhibitors, ARBs, thiazides, calcium-channel blockers, and beta blockers |
The closest substitutes are lisinopril/hydrochlorothiazide and losartan/hydrochlorothiazide. Both benefit from broad generic availability and stronger contemporary prescribing familiarity than quinapril in many markets.
Quinapril also faces clinical substitution because prescribers can use other ACE inhibitors with longer or more established market histories. Hydrochlorothiazide remains widely available as a low-cost separate product, reducing the commercial value of a fixed-dose quinapril combination.
What generic entry risks exist for Accuretic?
Generic-entry risk is no longer a future risk for Accuretic. It has already occurred.
The current issue is generic supply continuity and regulatory compliance. A manufacturer that markets quinapril/hydrochlorothiazide must control nitrosamine formation and demonstrate acceptable impurity levels. This raises manufacturing and testing costs but does not create durable pricing power unless supply becomes constrained.
Generic launch scenarios
| Scenario |
Market effect |
| Multiple generic suppliers |
Very low prices and rapid substitution |
| Limited generic supply |
Temporary price increases or pharmacy-level shortages |
| No commercially viable quinapril/HCTZ supplier |
Migration to separate components and other combinations |
| Pfizer re-entry |
Low probability of meaningful premium pricing because of generic competition |
| Impurity findings in additional suppliers |
Further contraction of the quinapril combination market |
The most probable long-term outcome is continued substitution away from Accuretic and toward other low-cost antihypertensive regimens.
Which companies are challenging Accuretic’s market position?
The competitive threat comes primarily from generic manufacturers and sponsors of alternative fixed-dose combinations, not from a single patent challenger.
Potential competitors include manufacturers of:
- Generic quinapril/hydrochlorothiazide.
- Generic lisinopril/hydrochlorothiazide.
- Generic losartan/hydrochlorothiazide.
- Generic valsartan/hydrochlorothiazide.
- Separate quinapril and hydrochlorothiazide products.
Publicly available information does not establish a current, commercially significant Paragraph IV campaign against Accuretic. Any historical ANDA litigation would have been overtaken by the expiration of the underlying patent estate and the product’s subsequent discontinuation.
What litigation and settlement agreements affect Accuretic?
No current high-value patent litigation or settlement agreement is central to Accuretic’s market outlook.
Historical litigation, if any, would have related to generic ANDA filings, patent certification, or product claims during the period when the brand had remaining patent value. Those disputes no longer create an effective barrier to generic substitution.
The material legal and regulatory issue is the 2022 impurity-related recall. That event affected manufacturing, distribution, and patient switching, but it did not create a new patent monopoly or extend Accuretic’s exclusivity.
How strong is the Accuretic patent estate?
Accuretic has a weak current patent estate.
| Patent factor |
Assessment |
| Core molecule |
Expired |
| Fixed-dose combination |
Expired or commercially irrelevant |
| Formulation protection |
No meaningful current barrier identified |
| Method-of-use protection |
No meaningful current barrier identified |
| Manufacturing know-how |
Potentially relevant but nonexclusive |
| Regulatory exclusivity |
Expired |
| Litigation leverage |
Minimal |
| Commercial defensibility |
Low |
Manufacturing controls may still be proprietary, particularly methods that limit quinapril-related nitrosamine formation. Those controls can affect cost, quality, and supply reliability. They do not prevent other manufacturers from developing their own compliant processes.
What formulations and methods are protected by Accuretic?
The commercial product is an immediate-release oral tablet containing quinapril hydrochloride and hydrochlorothiazide. Any historical formulation claims would have been directed to the fixed-dose composition, tablet manufacture, stability, or therapeutic use.
Those claims do not provide current market protection. The product’s present technical barrier is quality control:
- Controlling nitrosamine formation during synthesis.
- Monitoring active pharmaceutical ingredient and finished-product impurities.
- Managing packaging and storage conditions.
- Maintaining dissolution and bioequivalence.
- Demonstrating stability throughout shelf life.
For a returning manufacturer, these requirements could be more important than historical patent claims.
Does Accuretic have biosimilar risk?
No. Biosimilar competition does not apply because Accuretic is a chemically synthesized small-molecule tablet, not a biologic.
The relevant competitors are generic drugs approved under the ANDA pathway. Their commercial risk is substitution, price erosion, and supply competition rather than biosimilar interchangeability.
What is Accuretic’s geographic coverage?
Accuretic’s strongest historical commercial relevance was in the United States under Pfizer’s brand. The product’s current United States outlook is defined by discontinuation and generic substitution.
Internationally, quinapril/hydrochlorothiazide may have been marketed under different brand names, local sponsors, or generic labels. Geographic conclusions cannot be transferred directly from the United States because approval status, patent expiry, impurity actions, and reimbursement differ by jurisdiction.
The global IP position is nevertheless mature. Any country-specific patent rights associated with the original product would generally have expired by the current period, while local regulatory actions may determine whether products remain available.
What is the likely revenue outlook for Accuretic?
Accuretic has no credible standalone growth trajectory.
| Revenue driver |
Outlook |
| Brand volume |
Near zero after discontinuation |
| Brand price |
No sustainable premium |
| Generic volume |
Dependent on supplier availability |
| Generic price |
Low under multi-source competition |
| Reimbursement |
Favors cheaper alternatives |
| Re-launch economics |
Weak without a differentiated formulation |
| Pfizer financial exposure |
Immaterial relative to company-wide revenue |
Any future commercial opportunity would require a compliant reintroduction, stable supply, and a reason for physicians or payers to prefer quinapril/hydrochlorothiazide over widely available alternatives. The product has no obvious pricing or clinical differentiation to support that investment.
Key takeaways
- Accuretic is a discontinued Pfizer combination of quinapril hydrochloride and hydrochlorothiazide.
- FDA-related commercial withdrawal followed detection of elevated N-nitroso-quinapril in 2022.
- Core patent and regulatory exclusivity expired years before the withdrawal.
- No current patent estate creates a meaningful barrier to generic competition.
- Accuretic is a small-molecule drug and has no biosimilar exposure.
- Public filings do not provide a separate Accuretic revenue line; product-level financial exposure was likely immaterial at withdrawal.
- The main market outcome is substitution to separate components, other ACE inhibitor/thiazide combinations, and ARB/thiazide products.
- The remaining technical barrier is impurity control, not patent protection.
- A Pfizer re-launch would face weak economics because the market is mature, genericized, and clinically crowded.
FAQs
Is Accuretic still available by prescription?
The Pfizer-branded product was discontinued following the 2022 recall. Availability of any generic quinapril/hydrochlorothiazide product depends on current manufacturer supply and regulatory status.
What replaced Accuretic?
Common substitutes include separate quinapril and hydrochlorothiazide tablets, lisinopril/hydrochlorothiazide, losartan/hydrochlorothiazide, and other guideline-supported antihypertensive combinations.
Was Accuretic recalled because it was ineffective?
No. The recall was associated with elevated N-nitroso-quinapril, a nitrosamine impurity concern. The issue was product quality and contamination control, not a finding that quinapril or hydrochlorothiazide lacked antihypertensive efficacy.
Can a generic manufacturer launch Accuretic without Pfizer’s consent?
A manufacturer generally can seek approval for the generic combination through the ANDA pathway after applicable exclusivity and patent barriers have expired. Current launchability depends on FDA requirements, bioequivalence, manufacturing compliance, and impurity controls.
Is quinapril still commercially relevant after Accuretic’s withdrawal?
Quinapril has limited commercial relevance compared with more widely used ACE inhibitors and ARBs. The withdrawal of Accuretic further reduces its market visibility by removing a branded fixed-dose combination and encouraging therapeutic substitution.
References
-
U.S. Food and Drug Administration. (2022). Pfizer voluntarily recalls all lots of Accuretic and generic quinapril/hydrochlorothiazide tablets due to N-nitroso-quinapril impurity. FDA Drug Safety and Availability.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.
-
Pfizer Inc. (2022). Product recall information for Accuretic and quinapril/hydrochlorothiazide tablets. Pfizer product and safety communications.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (2024). Nitrosamine impurity guidance for industry: Control of nitrosamine impurities in human drugs. FDA.
